EGFR
All Product Categories
-
EGFR Inhibitors
(581)
View all products
-
EGFR Agonist
(1)
View all products
-
EGFR Antagonist
(1)
View all products
-
EGFR Activators
(5)
View all products
-
EGFR Modulators
(6)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(4)
View all products
-
EGFR Degraders
(22)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(13)
View all products
-
EGFR Related Products (757)
Related Products (757)
-
AFM24
0 ImagesCat. No.: HY-P990314AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 196.34 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
-
(E/Z)-Afatinib
0 ImagesSynonyms: (E/Z)-BIBW 2992(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.
-
AZ7550 Mesylate
0 ImagesSynonyms: AZ7550 trimesylate saltAZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
-
Imgatuzumab
0 ImagesSynonyms: RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody
-
PDZ1i
0 ImagesSynonyms: 113B7PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer.
-
Camelliaside A
0 ImagesCamelliaside A is a phytochemical and also a HER2 ligand. Camelliaside A shows no inhibitory effect on mycelial growth of Rhizoctonia solani, indicating no antifungal activity against this pathogen. Camelliaside A is applicable to breast cancer-related research.
-
Mogroside IV-A
0 ImagesMogroside IV-A is a triterpene glycoside found in Siraitia and acts as a PLSCR1 inhibitor. Mogroside IV-A inhibits PLSCR1-promoted EGFR phosphorylation and downstream MAPK signaling activation. Mogroside IV-A inhibits TPA (HY-18739)-induced activation of viral early antigen (EBV-EA). Mogroside IV-A enhances the anticancer effect of Epirubicin (HY-13624) and reverses acquired resistance of cells to Epirubicin. Mogroside IV-A is used in research related to triple-negative breast cancer and herpesvirus infection.
-
Peruvoside
0 ImagesPeruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.
-
BAY 2476568
0 ImagesBAY 2476568 is a potent and mutant-selective inhibitor targeting EGFR exon20 insertion variants. BAY 2476568 potently inhibits the kinase activity of EGFR exon20 insertion mutants (insASV, insSVD, insNPG) with IC50 values of 0.09 nM, 0.21 nM, and 0.11 nM, respectively. BAY 2476568 inhibits EGFR (Y1068) phosphorylation and reduces the phosphorylation of ERK1/2 and Akt (S473) in Ba/F3 cells expressing EGFR exon20 insertion mutants (insASV, insSVD). BAY 2476568 can be used for the study of non-small cell lung cancer (NSCLC) driven by EGFR exon20 insertion mutations.
-
ALK-IN-1
0 ImagesSynonyms: Brigatinib analogALK-IN-1 is an orally active, blood-brain barrier-permeable ALK and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer.
-
CH7233163
0 ImagesCH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities.
-
Fepixnebart
0 ImagesCat. No.: HY-P990071CAS No.: 2489584-93-0Synonyms: LY-3016859Fepixnebart (LY3016859) is a humanized monoclonal hIgG4 antibody, which binds and neutralizes only TGFα and epiregulin with high affinity. Fepixnebart can be used for the study of diabetic nephropathy and broad-spectrum chronic pain, including diabetic peripheral neuropathic pain (DPNP), signs and symptoms of osteoarthritis (OA), and chronic low back pain (CLBP).
-
Laprituximab
0 ImagesSynonyms: J2898A
